SEERS Hosts NDR Led by Daishin Securities – Update on thynC™ Business, FDA Approval, and Middle East Entry

Investor Relations Event: SEERS will hold an NDR on June 9, 2026 for domestic institutional investors
Key Topics: thynC™ business progress, US FDA approval timeline, Middle East market entry achievements
Sponsor: Daishin Securities, conducted via one-on-one and small group meetings
IR materials to be posted on KRX KIND system
[AI Summary]This disclosure is a routine IR activity without capital raising or equity changes; its direct impact on short-term stock price is limited, but it strengthens communication with institutional investors, making it a neutral event